Loading...
Loading...
Illumina
ILMN today announced that it received premarket
clearance from the U.S. Food and Drug Administration (FDA) for the
MiSeqDx system, the first high-throughput DNA sequencing analyzer to
receive FDA clearance. Illumina also received FDA premarket clearance
for the MiSeqDx Cystic Fibrosis 139-Variant Assay, MiSeqDx Cystic
Fibrosis Clinical Sequencing Assay, and MiSeqDx Universal Kit.
The MiSeqDx benchtop sequencer offers users the ability to run
diagnostic or research applications on a single, easy-to-use system. Designed
and validated for the clinical market, the MiSeqDx with the portfolio of
FDA-cleared in vitro diagnostic kits and assays leverage
Illumina's sequencing by synthesis (SBS) chemistry for high confidence
in results.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in